Tekla Capital Management’s Caribou Biosciences CRBU Stock Holding History

Tekla Capital Management’s Portfolio CRBU Stock Details CRBU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$2.41M	Hold	567,147	–	–	0.09%	107
2023 Q1	$3.01M	Hold	567,147	–	–	0.11%	100
2022 Q4	$3.56M	Hold	567,147	–	–	0.13%	86
2022 Q3	$5.98M	Sell	567,147 -132,230	-19%	-$1.23M	0.24%	72
2022 Q2	$3.8M	Hold	699,377	–	–	0.15%	94
2022 Q1	$6.42M	Hold	699,377	–	–	0.23%	82
2021 Q4	$9.88M	Hold	699,377	–	–	0.32%	69
2021 Q3	$15.6M	Buy	+699,377	New	+$17.1M	0.5%	53

Other funds holding CRBU

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

RCMU

Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EWM

Elmwood Wealth Management Berkeley, California $400M AUM 17.81% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Tekla Capital Management's CRBU Position: Q2 2023 in Review

Tekla Capital Management held its Caribou Biosciences (CRBU) position steady in Q2 2023 at 567,147 shares worth $2.41M. The position accounts for 0.09% of the portfolio, ranked #107.

Tekla Capital Management first reported a position in CRBU in Q3 2021 and has held it in 8 quarters since. The position peaked at $15.6M in Q3 2021. 121 funds tracked by Wall St. Rank hold CRBU as of Q2 2023.

Tekla Capital Management held 567,147 shares of Caribou Biosciences worth $2.41M as of Q2 2023.
Tekla Capital Management left its Caribou Biosciences share count unchanged in Q2 2023.
Caribou Biosciences made up 0.09% of Tekla Capital Management's portfolio in Q2 2023, its #107 holding.
Tekla Capital Management first reported a position in Caribou Biosciences in Q3 2021 and has held it in 8 quarters since.
Tekla Capital Management's Caribou Biosciences position peaked at $15.6M in Q3 2021.
121 funds tracked by Wall St. Rank held Caribou Biosciences as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.